{"id":"NCT00765895","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","briefTitle":"Nortriptyline for Idiopathic Gastroparesis","officialTitle":"Nortriptyline for Idiopathic Gastroparesis: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Trial (NORIG)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-01","primaryCompletion":"2012-10","completion":"2012-10","firstPosted":"2008-10-03","resultsPosted":"2015-04-16","lastUpdate":"2020-05-14"},"enrollment":130,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Idiopathic Gastroparesis"],"interventions":[{"type":"DRUG","name":"Nortriptyline Hydrochloride","otherNames":["Nortriptyline HCl","Pamelor"]},{"type":"DRUG","name":"Placebo (for nortriptyline)","otherNames":[]}],"arms":[{"label":"Nortriptyline","type":"ACTIVE_COMPARATOR"},{"label":"Placebo (for nortriptyline)","type":"PLACEBO_COMPARATOR"}],"summary":"The principal objective of this multicenter, randomized, placebo-controlled trial is to evaluate whether treatment with nortriptyline will improve gastroparesis symptoms compared with placebo.","primaryOutcome":{"measure":"Decrease From the Baseline GCSI of at Least 50% on Any Two Consecutive Follow-up Visits","timeFrame":"at end of treatment, 15 weeks from baseline assessment","effectByArm":[{"arm":"Nortriptyline","deltaMin":15,"sd":null},{"arm":"Placebo","deltaMin":14,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.86"}]},"eligibility":{"minAge":"21 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":18},"locations":{"siteCount":7,"countries":["United States"]},"refs":{"pmids":["24368464"],"seeAlso":["https://jhuccs1.us/gpcrc/"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":65},"commonTop":["cardiac","gastrointestinal events","Nervous system","renal and urinary events","psychiatric"]}}